<DOC>
	<DOCNO>NCT00032968</DOCNO>
	<brief_summary>The purpose study ass buprenorphine/naloxone versus clonidine outpatient opiate detoxification .</brief_summary>
	<brief_title>Buprenorphine/Naloxone Versus Clonidine Outpatient Opiate Detoxification - 1</brief_title>
	<detailed_description>Patients randomize BUP/NX arm receive daily dos 13 day sublingual administration 2 mg buprenorphine/0.5 mg naloxone tablet ( ) and/or 8 mg buprenorphine/2.0 mg naloxone tablet ( ) . The start dose day 1 4 mg/1 mg BUP/NX additional 4 mg/1 mg , need , escalate step-wise manner 16 mg/4 mg BUP/NX day 3 taper 2 mg/ 0.5 mg BUP/NX day 12 13 . Patients randomized clonidine arm receive oral clonidine ( 0.05 0.1 mg depend upon weight ) every 4 6 hour 24 hour exceed 0.6 mg total day 1 . On day 2 , clonidine transdermal patch apply ( 0.1 mg/day/7-day patch number patch adjust weight ) . Oral clonidine continue give second day detoxification increase 0.2 mg every 6 hour 0.1 mg every 3 hour exceed 0.8 mg 24 hour . Patches wear 13 day detoxification . The dose clonidine adjust accord propose detoxification schedule , patient 's weight , tolerance , systolic blood pressure . Patients receive counsel accord procedure existence CTP throughout study . Self-help detoxification handbook distribute study participant .</detailed_description>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Heroin Dependence</mesh_term>
	<mesh_term>Morphine Dependence</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>1 . Treatmentseeking male nonpregnant nonlactating female , 15 year old , fulfill DSMIV criterion opiate dependence , report experience symptom opiate withdrawal , currently physically dependent opioids need medical assistance opioid withdrawal . 2 . Systolic blood pressure 100 mm Hg , pulse 56 bpm . 3 . Good general health , case medical/psychiatric condition need ongoing treatment , care physician willing continue patient 's medical management cooperate study physician . 4 . Agreeable capable signing informed consent approve institutional review board , age 18 ( exclude emancipate minor ) , assent concurrent consent parent legal guardian . 5 . Use one follow acceptable method birth control female patient childbearing potential : 1. oral contraceptive 2. barrier ( diaphragm cervical cap ) spermicide condom 3. intrauterine progesterone contraceptive system 4. levonorgestrel implant 5. medroxyprogesterone acetate contraceptive injection 6. complete abstinence sexual intercourse 1 . Medical condition would make participation , opinion study physician , medically hazardous ( e.g. , acute hepatitis , unstable cardiovascular , liver renal disease ) ; 2 . Clinically significant abnormality ECG . 3 . Known allergy sensitivity buprenorphine , naloxone , clonidine . 4 . Receiving betablockers , calcium channel blocker , tricyclic , digitalis medication may interact adversely clonidine . 5 . Acute severe psychiatric condition need immediate treatment , imminent suicide risk . 6 . Dependence alcohol , benzodiazepines depressant , stimulant , require immediate medical attention . 7 . Participation investigational drug study , include buprenorphine , within past 30 day . 8 . Methadone LAAM maintenance detoxification within 30 day enrollment . 9 . Pending legal action could prohibit interfere participation . 10 . Unable remain area duration active phase treatment . 11 . Females pregnant , lactating , plan become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>opiate dependence</keyword>
</DOC>